RedHill Biopharma (RDHL) Net Income towards Common Stockholders (2012 - 2023)

RedHill Biopharma (RDHL) has reported Net Income towards Common Stockholders for 12 consecutive years, with $58.9 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Net Income towards Common Stockholders rose 294604999900.0% year-over-year to $58.9 million; the TTM figure through Dec 2024 stood at $58.9 million (up 418.17% YoY), while the FY2025 annual figure was $7.7 million, up 192.54% from the prior year.
• Net Income towards Common Stockholders climbed to $58.9 million in Q2 2023 per RDHL's latest filing, from -$7.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $58.9 million in Q2 2023 and bottomed at -$142.2 million in Q4 2021.
• Historically, Net Income towards Common Stockholders has averaged -$2.9 million across 5 years, with a median of $10.3 million in 2019.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 1449.66% — and 2023, when it soared 294604999900.0%.
• RedHill Biopharma's Net Income towards Common Stockholders stood at $11.8 million in 2019, then retreated by 10.99% to $10.5 million in 2020, then sank by 1449.66% to -$142.2 million in 2021, then soared by 51.11% to -$69.5 million in 2022, then soared by 184.75% to $58.9 million in 2023.
• Business Quant data shows RDHL's Net Income towards Common Stockholders at $58.9 million in Q2 2023, -$7.9 million in Q1 2023, and -$69.5 million in Q4 2022.